Matinas BioPharma Holdings, Inc. (MTNB) stock
MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)
Close on Nov 18, 2026Market cap $13.37MP/E –Yield –
Matinas BioPharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Matinas BioPharma's profit margin for the twelve months ending Dec 31, 2023 was -2093.2%. For fiscal 2023 it was -2093.2%, against -658.6% the year before. The highest annual figure on record is -658.6% in fiscal 2022.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -2093.2% | −1434.6 |
| FY2022 | Dec 31, 2022 | -658.6% | +69895.9 |
| FY2021 | Dec 31, 2021 | -70554.5% | −56377.6 |
| FY2020 | Dec 31, 2020 | -14177.0% | +5166.4 |
| FY2019 | Dec 31, 2019 | -19343.4% | −7583.0 |
| FY2018 | Dec 31, 2018 | -11760.4% | −1414.5 |
| FY2017 | Dec 31, 2017 | -10345.9% | −5648.9 |
| FY2015 | Dec 31, 2015 | -4697.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | -503.0% | +14366.1 |
| Q4 FY2022 | Dec 31, 2022 | -341.9% | +9803.5 |
| Q3 FY2022 | Sep 30, 2022 | -513.8% | +5172.6 |
| Q2 FY2022 | Jun 30, 2022 | -557.2% | +3166.9 |
| Q1 FY2021 | Mar 31, 2021 | -14869.1% | −11071.2 |
| Q4 FY2020 | Dec 31, 2020 | -10145.4% | +3583.4 |
| Q3 FY2020 | Sep 30, 2020 | -5686.5% | +2392.7 |
| Q2 FY2019 | Jun 30, 2019 | -3724.1% | +3835.5 |
| Q2 FY2018 | Jun 30, 2018 | -3797.9% | +5037.5 |
| Q1 FY2018 | Mar 31, 2018 | -13728.8% | +16307.3 |
| Q4 FY2017 | Dec 31, 2017 | -8079.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -7559.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -8835.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -30036.2% | – |
See a number that looks wrong?